Intuitive Surgical stock jumps on heavy volume as ISRG nears 52-week high ahead of key January dates

7 January 2026

New York, January 6, 2026, 21:40 EST — Market closed

Intuitive Surgical shares closed up 4.7% on Tuesday, extending a two-day rise
Focus turns to the company’s Jan. 14 conference presentation and Jan. 22 quarterly call
Traders watch Wednesday’s U.S. data for interest-rate cues that can sway growth stocks

Intuitive Surgical (ISRG) shares rose 4.7% on Tuesday to close at $592.85, outpacing several large-cap medical device peers as U.S. stocks advanced broadly. MarketWatch

The gain left the surgical-robot maker about 3.8% below its 52-week high of $616, a level some investors view as a near-term marker after the stock’s sharp run since early January. MarketWatch

That matters now because Intuitive is entering a stretch when management commentary can reset expectations, with investors looking for early signals on demand and margins before the next earnings update. Intuitive

Tuesday’s session was active. ISRG traded about 2.6 million shares, above its 50-day average of 1.8 million, and swung between roughly $564 and $595, market data showed. MarketWatch

Intuitive is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on Jan. 14. It has also listed a fourth-quarter 2025 earnings conference call for Jan. 22 at 1:30 p.m. PST (4:30 p.m. ET). Intuitive

Investors will be listening for updates on procedure growth, hospital capital spending and gross margin — the share of revenue left after production costs — after the company previously raised its 2025 adjusted gross margin forecast in its October results. Reuters

Still, the setup cuts both ways. Intuitive trades at a premium to many medtech peers, and any sign of slower procedure growth, pricing pressure, or higher costs could sharpen the stock’s swings into results. MarketWatch

Before the next session, traders also face a slate of U.S. releases on Wednesday including ADP employment, the ISM services index and the JOLTS job openings report, all of which can move rate expectations and high-multiple stocks. The next company checkpoints are Jan. 14 and Jan. 22. Intuitive

Khadija Saeed Latest posts

A dedicated markets reporter, she covers stocks, macroeconomics, and major business developments with a sharp eye for detail and accuracy.

View all

Spirax Group fair value held at £77.42 as inputs shift; UBS turns Buy, JPMorgan stays Neutral
January 8, 2026, 9:17 PM EST. Spirax Group's updated model keeps the fair value per share anchored at £77.42 despite only marginal input tweaks. The changes - a notch higher discount rate to 9.18% and a slim trim to revenue growth to 4.58% - reflect a valuation built on fine tuning rather than new assumptions. Spirax reaffirmed its 2025 guidance, showing organic revenue growth steady with 2024 levels and IP-relative activity as a reference point. In market color, UBS lifted its stance to Buy with a target of 10,500 GBp, signaling optimism on long-term growth. JPMorgan remains Neutral with a 7,500 GBp target. The forward P/E ticked to 29.79x from 29.74x, echoing modest upside tempered by execution risk.